FNY Investment Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

FNY Investment Advisers’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23K	Hold	5,000	–	–	0.01%	513
2026 Q1	$26K	Hold	5,000	–	–	0.01%	441
2025 Q4	$17K	Hold	5,000	–	–	﹤0.01%	588
2025 Q3	$14K	Hold	5,000	–	–	﹤0.01%	737
2025 Q2	$18K	Hold	5,000	–	–	0.01%	567
2025 Q1	$14K	Buy	+5,000	New	+$15.6K	0.01%	441
2023 Q3	–	Sell	-1,521	Closed	-$5K	–	608
2023 Q2	$5K	Buy	+1,521	New	+$5.69K	0.01%	365

Other funds holding AVIR

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Auour Investments Woburn, Massachusetts $349M AUM 13.68% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

JIC

Johnson Investment Counsel Cincinnati, Ohio $13.7B AUM 21.52% 1-Year Est. Return

CAC

Certified Advisory Corp Altamonte Springs, Florida $1.24B AUM 21.71% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

FNY Investment Advisers's AVIR Position: Q2 2026 in Review

FNY Investment Advisers held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 5,000 shares worth $23K. The position accounts for 0.01% of the portfolio, ranked #513.

FNY Investment Advisers first reported a position in AVIR in Q2 2023 and has held it in 7 quarters since. The position peaked at $26K in Q1 2026. 25 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

FNY Investment Advisers held 5,000 shares of Atea Pharmaceuticals worth $23K as of Q2 2026.
FNY Investment Advisers left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #513 holding.
FNY Investment Advisers first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
FNY Investment Advisers's Atea Pharmaceuticals position peaked at $26K in Q1 2026.
25 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.